Anatomic Stage IV Breast Cancer AJCC v8 Clinical Trials

46 recruiting

Anatomic Stage IV Breast Cancer AJCC v8 Trials at a Glance

46 actively recruiting trials for anatomic stage iv breast cancer ajcc v8 are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 23 trials, with the heaviest enrollment activity in Columbus, Oklahoma City, and St Louis. Lead sponsors running anatomic stage iv breast cancer ajcc v8 studies include National Cancer Institute (NCI), Mayo Clinic, and City of Hope Medical Center.

Browse anatomic stage iv breast cancer ajcc v8 trials by phase

Treatments under study

About Anatomic Stage IV Breast Cancer AJCC v8 Clinical Trials

Looking for clinical trials for Anatomic Stage IV Breast Cancer AJCC v8? There are currently 46 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Anatomic Stage IV Breast Cancer AJCC v8 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Anatomic Stage IV Breast Cancer AJCC v8 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 46 trials

Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaInvasive Breast Carcinoma
National Cancer Institute (NCI)70 enrolled30 locationsNCT03606967
Recruiting
Phase 2

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more
Roswell Park Cancer Institute30 enrolled1 locationNCT06434064
Recruiting
Phase 2

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast Carcinoma+3 more
University of Washington60 enrolled2 locationsNCT06179303
Recruiting
Phase 2

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma
Emory University29 enrolled1 locationNCT06492759
Recruiting
Phase 1

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+2 more
National Cancer Institute (NCI)57 enrolled6 locationsNCT05422794
Recruiting
Phase 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494
Recruiting
Phase 1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+5 more
National Cancer Institute (NCI)45 enrolled7 locationsNCT05372640
Recruiting
Phase 1

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled1 locationNCT07137416
Recruiting
Phase 1

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more
National Cancer Institute (NCI)32 enrolled10 locationsNCT05673200
Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Phase 3

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Lung Non-Small Cell Carcinoma+2 more
NRG Oncology115 enrolled58 locationsNCT06500481
Recruiting
Phase 3

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Lung Non-Small Cell Carcinoma+7 more
NRG Oncology269 enrolled263 locationsNCT06500455
Recruiting
Phase 2

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma
University of Washington20 enrolled1 locationNCT07078604
Recruiting
Phase 2

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
University of Washington40 enrolled1 locationNCT07112053
Recruiting
Not Applicable

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8HER2/Neu Negative+3 more
SWOG Cancer Research Network739 enrolled723 locationsNCT03723928
Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting
Not Applicable

Mobile Health for Adherence in Breast Cancer Patients

Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8+1 more
ECOG-ACRIN Cancer Research Group410 enrolled400 locationsNCT06112613
Recruiting
Not Applicable

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaStage IV Lung Cancer AJCC v8+2 more
Mayo Clinic5 enrolled1 locationNCT05746325
Recruiting

Living Well With Advanced Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaAdvanced Breast Carcinoma
Ohio State University Comprehensive Cancer Center50 enrolled1 locationNCT07227038